Background: Type 2 diabetes mellitus represents high proportion of diabetics which is mainly due to obesity and insulin resistance. Obesity is asscoiated with many co-morbidities like type 2 DM, cardiovascular (CV) complications, hypertension and dyslipidymia. Laparoscopic sleeve gastrectomy (LSG) was used as the first stage in a multistage procedure in obese patients with at least two severe co-morbidities. Two years after sleeve gastrectomy, more than 50% of those patients showed resolution of their co morbidities. Bariatric surgery has emerged as a highly effective management for morbid obesity and many related co-morbidities, including type 2 diabetes mellitus (T2DM). However, it has recently been approved that LSG is more than a gastric restrictive operation. It has been suggested that the changes in ghrelin and peptide YY after LSG may help to explain the weight loss results. So the aim of this study was to evaluate the effect of laparoscopic sleeve gastrectomy (LSG) on obese patients with type 2 DM.   Methods: This study was conducted on 30 obese patients suffering from T2DM (9 males and 21 females) who underwent laparoscopic sleeve gastrectomy at the Ain Shams University Hospital (El-Demerdash) and Ain Shams Specialized Hospital. Follow up of the patients was done for a period of 6 months to investigate their HbA1c changes and diabetic status.   Results: Our results showed significant reduction in the mean level of HbA1c (p < 0.001) at 6 months follow-up post-surgery, with 16.7% (5 patients) completely cured from T2DM while 40% (12 patients) became pre-diabetic and 43.3% (13 patients) remained diabetic.   Conclusion: Most patients with type 2 DM experience resolution or improvement in diabetic status after LSG. LSG might play an important role as a metabolic therapy for patients with type 2 DM.